多生物标志物疾病活动度评分与类风湿关节炎患者动脉18-氟脱氧葡萄糖摄取的相关性
在TARGET试验中,活动性类风湿关节炎患者随机接受TNF抑制剂或柳氮磺吡啶+羟氯喹治疗,基线和24周行动脉[18F]氟脱氧葡萄糖-PET/CT评估。112例可评估患者中,24周MBDA评分与动脉炎症变化显著相关(Spearman's rho=0.239;P=0.011),低MBDA者动脉炎症调整后降低0.35单位。
要点
- 24周MBDA评分与动脉炎症变化显著相关(Spearman's rho=0.239;P=0.011)。
- 24周达到低MBDA者动脉炎症调整后降低0.35单位,未达到者无显著降低。
- DAS28-CRP和CRP均不能预测动脉炎症变化。
核心结论
- 在接受治疗的类风湿关节炎患者中,达到的MBDA评分可预测动脉炎症变化。
- 24周达到低MBDA与动脉炎症的临床有意义降低相关,且与治疗方案无关。
研究设计与样本
- TARGET试验为干预性试验,活动性类风湿关节炎患者在接受甲氨蝶呤治疗仍活动时,随机分配至加用TNF抑制剂或柳氮磺吡啶+羟氯喹(三联疗法)。
- 基线和24周随访行[18F]氟脱氧葡萄糖-PET/CT扫描,评估颈动脉或主动脉最病变段的最大动脉靶/血本底比值(MDS-TBRmax)变化。
- MBDA检测于基线及第6、18、24周进行,评估其与MDS-TBRmax变化的相关性。
- 基线和第24周有可解读扫描的患者共112例。
主要发现
- 24周MBDA评分与MDS-TBRmax变化显著相关(Spearman's rho=0.239;P=0.011),调整相关混杂因素后仍显著相关。
- 24周低MBDA者动脉炎症调整后降低0.35单位,未达到低MBDA者无显著降低。
- DAS28-CRP和CRP均不能预测动脉炎症变化。
- 与动脉炎症变化相关性最强的MBDA组分为血清淀粉样蛋白A。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Rheumatoid arthritis (RA) and atherosclerosis share many common inflammatory pathways. We studied whether a multi-biomarker panel for RA disease activity (MBDA) would associate with changes in arterial inflammation in an interventional trial. METHODS: In the TARGET Trial, RA patients with active disease despite methotrexate were randomly assigned to the addition of either a TNF inhibitor or sulfasalazine+hydroxychloroquine (triple therapy). Baseline and 24-week follow-up [18F]fluorodeoxyglucose-PET/CT scans were assessed for change in arterial inflammation measured as the maximal arterial target-to-blood background ratio of FDG uptake in the most diseased segment of the carotid arteries or aorta (MDS-TBRmax). The MBDA test, measured at baseline and weeks 6, 18 and 24, was assessed for its association with the change in MDS-TBRmax. RESULTS: Interpretable scans were available at baseline and week 24 for 112 patients. The MBDA score at week 24 was significantly correlated with the change in MDS-TBRmax (Spearman's rho = 0.239; P = 0.011) and remained significantly associated after adjustment for relevant confounders. Those with low MBDA at week 24 had a statistically significant adjusted reduction in arterial inflammation of 0.35 units vs no significant reduction in those who did not achieve low MBDA. Neither DAS28-CRP nor CRP predicted change in arterial inflammation. The MBDA component with the strongest association with change in arterial inflammation was serum amyloid A. CONCLUSION: Among treated RA patients, achieved MBDA predicts changes in arterial inflammation. Achieving low MBDA at 24 weeks was associated with clinically meaningful reductions in arterial inflammation, regardless of treatment.
引用
- Giles JT, Solomon DH, Liao KP, et al. Association of the multi-biomarker disease activity score with arterial 18-fluorodeoxyglucose uptake in rheumatoid arthritis. Rheumatology (Oxford). 2025. PMID: 38652572. doi:10.1093/rheumatology/keae242
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。